Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
Mostafa Faisal Mohammed Saleh, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn:
”Twenty Years in Hematology: From the Palpable Spleen to Cellular Therapy
A personal journey, 2006–2026
Part 2
At the same time, I began to get deeply involved in stem cell transplantation.
The possibility of curing diseases that had reached the limits of conventional treatment was extraordinary.
As physicians, we sometimes miss the immediate satisfaction our surgical colleagues experience after removing a tumor or repairing an organ.
Transplantation gave me a similar feeling: a patient with an otherwise fatal hematologic disease could undergo an extraordinarily complex treatment and potentially emerge cured.
A major turning point came in December 2013, when I joined the Cleveland Clinic as a research fellow in Histocompatibility and Immunogenetics. I entered what I thought of as ‘HLA land.’
I learned transplantation from another perspective—donor matching, HLA, KIR biology, immunogenetics, and their relationship to transplant outcomes.
Equally influential were the BMT rounds with physicians including Navneet Majhail and Ronald Sobecks, where laboratory immunology became directly connected to patients at the bedside.
My research during this period, including work on donor KIR genotype and transplantation outcomes, became closely linked to my PhD research in transplantation and pharmacogenetics.
After completing my PhD in Clinical Hematology and Stem Cell Transplantation in 2016, I continued patient care, teaching, and transplantation in Egypt.
Participating in the development of the first bone marrow transplantation experience in Upper Egypt in 2016 was particularly meaningful.
Bringing this potentially curative treatment closer to patients who previously had to travel to Cairo reinforced my belief that medical progress matters most when it becomes accessible to the patients who need it.”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation
-
Oct 25, 2026, 14:47Siddharth Mittal: A Sheet-Like Effluent Deposit During Plasma Exchange in iTTP
-
Oct 25, 2026, 14:16Alejandro González Veliz: Can Factor XIa Inhibition Prevent Recurrent Ischemic Events Without Increasing Bleeding?
-
Oct 25, 2026, 13:0910 Posts Not to Miss This Week
-
Oct 25, 2026, 13:02Thomas Dayspring: Advancing Cardiovascular Risk Assessment Through Multidisciplinary Lipid Care
-
Oct 25, 2026, 12:46Ahmar U. Zaidi: RISE UP Study on Sickle Cell Disease
-
Oct 25, 2026, 10:32Jan Sloves: Advanced Venous Ultrasound Training in Poland